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Rapid normalization of alanine aminotransferase predicts 
viral response during combined peginterferon and ribavirin 
treatment in chronic hepatitis C patients
Yun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, 
Woo Jin Chung, and Jae Seok Hwang
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
Background/Aims: The treatment for chronic hepatitis C (CHC) is removal of the virus in order to prevent progression to 
liver cirrhosis and hepatocellular carcinoma (HCC). Few data have been presented regarding the clinical significance of 
changes in the alanine aminotransferase (ALT) level in this context. We analyzed the patterns of changes in ALT level 
and investigated the relationship between the rapid normalization of ALT and sustained virologic response (SVR) after 
combined treatment with peginterferon and ribavirin. Methods: CHC patients (n=370) were classified into four groups 
according to the initial ALT level and subsequent changes: (1) initially abnormal ALT level and sustained abnormal ALT 
level during treatment, (2) initially abnormal ALT level but achievement of ALT normalization, (3) initially normal ALT level 
and variable ALT abnormality during treatment, and (4) initially normal ALT level and sustained normalization of ALT level 
during treatment. We subdivided groups 1 and 2 into those with patterns of decreased and normalization of ALT, with or 
without rapid normalization. We checked the end-treatment response (ETR) and SVR rates in each group and the factors 
associated with SVR, including patterns of changes in ALT level. Results: A total of 168 patients completed the therapy 
(age=54.34±10.64 years [mean±SD], 95 males [56.5%], genotype 1:82 [48.8%]). SVR was achieved in 115 (68.45%) of 
the completely treated patients. The SVR rate was significantly lower in group 1 than in group 2 (37.8 vs. 81.6%, 
P<0.001), and significantly higher in the rapid normalization group than in the group without rapid normalization (78.5% 
vs. 41.2%, P<0.001). Multiple logistic regression analysis revealed that age (odds ratio [OR]=0.94, 95% confidence 
interval [CI]=0.91-0.98, P=0.005), viral genotype (OR=2.76, 95% CI=1.20-6.38, P=0.017), and initial hepatitis C virus 
RNA titer (OR=0.28, 95% CI=0.10-0.75, P=0.012) were identified as independent significant predictive factors for SVR. 
Conclusions: The SVR rate is significantly associated with normalization, and especially rapid normalization of ALT. 
Rapid normalization of ALT by 4 weeks after treatment might be a useful response factor that is readily available in clinical 
practice, and especially for genotype 1 patients. (Korean J Hepatol 2012;18:41-47)
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INTRODUCTION
Hepatitis C virus (HCV) infection is an important cause of 
chronic liver disease and primary hepatocellular carcinoma 
(HCC) in the world.
1 The likelihood of achieving sustained 
virological response (SVR) could be predicted based on 
several factors, including virus genotype, age, sex, 
histological finding and initial HCV RNA titer. These 
factors have been reported in many previous studies,
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Figure 1. Schematic diagram showing patient group flow 
according to initial alanine aminotransferase (ALT) level and 
subsequent pattern of change. Group 1, initially abnormal ALT 
level and sustained abnormal ALT level during treatment. Group 
2, initially abnormal ALT level but achievement of ALT 
normalization. Group 3, initially normal ALT level and variable 
ALT abnormality during treatment. Group 4, initially normal
ALT level and sustained normalization ALT level during 
treatment.
the pattern of change in alanine aminotransferase (ALT) 
during treatment has not been completely established. In 
clinical practice, ALT is an important laboratory test marker, 
both inexpensive and readily available for monitoring HCV 
disease activity.
Therefore, the goal of this study was to evaluate the 
relationship between the patterns of change in ALT during 
treatment and virologic response to peg-interferon alpha and 
ribavirin combination treatment in chronic hepatitis C 
(CHC), and to establish the clinical meaning of rapid 
normalization of ALT. 
PATIENTS AND METHODS
Patients
We retrospectively reviewed the medical records of 
patients diagnosed with chronic hepatitis C who underwent 
peg-interferon alpha and ribavirin combination treatment 
from May 2004 to May 2010 at Keimyung University 
Dong San Hospital. A total 370 consecutive patients were 
considered for this study. Patients who were on treatment or 
withdrew because of adverse events or were lost during 
follow-up were excluded. We also excluded patients with 
human immune-deficiency virus infection, hepatitis B virus 
co-infection, alcohol abuse, autoimmue hepatitis and other 
causes of liver disease. Thus, final analyses included 168 
patients followed up for at least 6 months after completion of 
treatment.
Study design
ALT patterns were analyzed throughout the course of 
treatment and follow-up period. We categorized patients into 
four groups according to initial ALT levels and ALT 
variability during treatment: group 1, patients who had 
initial abnormal ALT levels and sustained abnormal ALT 
levels during treatment (Gr 1), group 2, patients who had 
initial abnormal ALT levels and obtained normalization of 
ALT (Gr 2), group 3, patients who had initial normal ALT 
levels and variable ALT abnormality during treatment (Gr 3) 
and group 4, patients who had initial normal ALT levels and 
sustained normal ALT levels during treatment (Gr 4) (Fig. 1). 
We compared the end treatment response (ETR) and SVR 
rates between groups, based on the eradication of virus 
(Table 1).
Also for analysis of decreased and normalization of ALT 
pattern, patients who had initial abnormal ALT levels (i.e. 
Gr 1 and 2) were subdivided into two groups: (1) patients 
who had initial abnormal ALT levels with rapid normalization, 
i.e. within 1.5 times of normal range of ALT 4 weeks after 
starting treatment and (2), patients who had initial abnormal 
ALT levels without rapid normalization, i.e. not within 1.5 
times of normal range of ALT 4 weeks after starting 
treatment.
Treatment with peg-interferon plus ribavirin
Patients with genotype 1 infection were subcutaneously 
administered 180 μg of peg-interferon alpha-2a (Pegasys
®, 
Roche, Seoul, Korea) or 1.5 μg/kg of peg-interferon alpha-2b 
(PEG-Intron
®, Schering Corp, Seoul, Korea) once a week, 
and orally administered 1,000 mg (for patient weighing <75 
kg) or 1,200 mg of ribavirin daily (for those weighing >75 
kg) for 48 weeks. Patients with genotype non-1 infections 
received the same dosage of peg-interferon alpha-2a or -2b 
and 800 mg per day of oral ribavirin for 24 weeks.Yun Jung Kim, et al. Clinical meaning about change in alanine aminotransferase  43
Table 1. Baseline demographic, clinical characteristics, and virologic responses in patients with different patterns of change in alanine 
aminotransferase (ALT) level during treatment (n=168)
Variable/group Gr 1
* (n=37) Gr 2
†  (n=76) Gr 3
‡ (n=15) Gr 4
§  (n=40) P-value
Age (years, mean±SD) 55.5±9.3
∥ 54.1±11.4
∥ 53.9±10.6
∥ 53.9±10.6
∥ 0.89
**
Gender (male, %) 21 (56.8) 48 (63.2) 7 (46.7) 19 (47.5) 0.35
††
BMI (kg/m
2, mean±SD) 24.4±3.2
∥ 23.6±2.7
∥ 24.3±2.2
∥ 23.9±2.8
∥ 0.52
**
Initial ALT (IU/L, mean±SD) 122.8±86.2
∥ 109.4±61.0
∥ 29.1±11.2
‡‡ 29.7±8.4
‡‡ <0.01
**
Initial APRI score 1.8±2.2
∥ 1.0±1.1
∥ 1.7±3.4
∥ 0.7±0.9
‡‡ 0.01
**
Cirrhosis confirmed by image 13 (35.1) 13 (17.1) 4 (26.7) 7( 1 7 . 5 ) 0.14
††
HCV genotype 1/non-1 (%) 20/17 (54.1/45.9) 36/40 (47.4/52.6) 6/9 (40/60) 20/20 (50/50) 0.81
††
HCV RNA (n, %) 0.19
††
  <400000 16 (43.2) 34 (44.7) 4 (26.7) 9 (22.5)
  ≥400000, <800000 10 (27.0) 16 (21.1) 3 (20.0) 10 (25.0)
  ≥800000 11 (29.7) 26 (34.2) 8 (53.3) 21 (52.5)
ETR (%) 31 (83.8) 70 (92.1) 13 (86.7) 38 (95) 0.34
††
SVR (%) 14 (37.8) 62 (81.6) 8 (53.3) 31 (77.5) <0.01
††
*Patients who had initial abnormal ALT levels and sustained abnormal ALT levels during treatment; 
†Patients who had initial 
abnormal ALT levels and obtained normalization of ALT; 
‡Patients who had initial normal ALT levels and variable ALT abnormality 
during treatment; 
§Patients who had initial normal ALT levels and sustained normal ALT levels during treatment; 
††Chi-squared test; 
**Anova test;
∥,‡‡Same symbols indicate no statistical significance based on Turkey’s HSD post-hoc test.
BMI, body mass index; ALT, alanine aminotransferase; APRI, AST (aspartate amine transferase) platelet ratio index; HCV, hepatitis 
C virus; ETR, end treatment response; SVR, sustained virologic response.
Clinical and laboratory assessment
We followed patients by performing blood samples and 
measuring biochemical variables. Blood samples were 
tested for complete blood counts (CBC), serum ALT levels, 
serum aspartate amine transferase (AST), HCV genotype 
(baseline only) and serum HCV RNA. Serum ALT levels 
were obtained from all patients at baseline and at weeks 
4, 12, 24 and 48 of peg-interferon alpha and ribavirin 
combination treatment, and 24 weeks after completing 
therapy. The upper normal for serum ALT was 45 IU/L. 
Body mass index (BMI) was calculated as weight in 
kilograms/height square in meters. AST platelet ratio index 
(APRI) score was calculated according to the formula 
proposed by Wai et al
4 in 2003, namely, [(AST/upper limit of 
normal)/platelet count (10
9/L)]×100. The reference value for 
AST was considered to be 40 IU/L, which is the upper 
normal limit in our laboratory.
Assessment of efficacy
The primary end point of efficacy was SVR. i.e. the 
undetectable serum HCV RNA levels at 24 weeks after 
completing treatment. ETR was defined as the undetectable 
serum HCV RNA level at the end of treatment. Virologic 
relapse was defined as the detectable HCV RNA level 
during follow-up in patients with previously undetectable 
HCV RNA level at the end of treatment.
Statistical analysis
Data management and statistical analyses were performed 
with SPSS software version 15.0 (SPSS Inc., Chicago, IL). 
Rates and proportions were calculated for categorical data. 
Means were calculated for continuous variables. The chi- 
square and Fisher’s exact tests were used to compare the 
distribution of categorical variables between the groups, 
respectively. To compare continuous variables among groups, 
Student’s t-test or ANOVA test was used as appropriate. 
Univariate analysis and multiple logistic regression were 
used to identify predictive factors for sustained response. 
In multiple logistic regression analysis, we determined the 
strength of influence of possible variables (age, viral genotype, 
HCV RNA titer and ALT variability) for sustained response. 
A P-value of  <0.05 was considered as statistically significant.44  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 2. Comparison of baseline clinical characteristics and virologic responses in patients with or without rapid normalization of an 
initially abnormal ALT level during treatment 
ALT normalization Group 1
* (n=79) Group 2
† (n=34) P-value
Age (years, mean±SD) 54.9±11.0 53.8±10.1 0.61
‡
Gender (male,%) 49 (62.0) 20 (58.8) 0.75
§
Initial ALT (IU/L, mean±SD) 105.3±51.7 133.3±99.1 0.05
‡
Genotype I (n, %) 39 (49.4) 17 (50.0) 0.95
§
ETR (n, %) 73 (92.4) 28 (82.4) 0.18
§
SVR (n, %) 62 (78.5) 14 (41.2) <0.01
§
*Patients who had initial abnormal ALT levels with rapid normalization, i.e. within 1.5 times of normal range of ALT 4 weeks after 
starting treatment; 
†Patients who had initial abnormal ALT levels without rapid normalization, i.e. not within 1.5 times of normal 
range of ALT 4 weeks after starting treatment; 
‡Student’s  t-test; 
§Chi-squared test.
ALT, alanine aminotransferase; ETR, end treatment response; SVR, sustained virologic response.
RESULTS
Patient demographics
Of the 370 patients, 202 patients withdrew because of 
adverse events, were lost during follow-up, or were on 
treatment or diagnosed with co-infection with hepatitis B or 
other liver disease. Total 168 patients followed up for at least 
6 months after treatment ended were finally enrolled. The 
baseline characteristics of the patients are summarized in 
Table 1. The mean age of patients was 54.34±10.64 years 
(range, 28-76 years). The gender distribution was 95 males 
and 73 female and the genotype distribution was 82 of 
genotype 1 and 86 of non-genotype 1.
Virologic responses according to ALT variability 
during treatment
For analysis purposes, patients were divided into four 
groups based on initial ALT levels and ALT variability during 
treatment. Of the 168 patients treated with peg-interferon- 
ribavirin combination, 115 (68.45%) showed SVR and 53 
(31.55%) showed non-sustained response. The ETR and 
SVR rates in the four groups were listed in Table 1. The ETR 
rates was not significantly different between the four groups. 
The SVR rate was significantly lower in group 1 compared 
with group 2 patients (37.8 vs. 81.6%, P-value <0.001), but 
was not different between group 3 and 4.
Virologic responses according to rapid/non-rapid 
normalization of ALT levels 4 weeks after treatment
For analysis purposes, the baseline characteristics of the 
patients who had initial abnormal ALT levels are summarized 
in Table 2. Baseline clinical characteristics including age, 
gender, initial ALT level and genotype were not different 
between the two groups. However, the SVR rate was 
significantly higher in rapid normalization group compared 
to without rapid normalization group (78.5 vs. 41.2%, P 
<0.001).
For subanalysis of SVR rates with or without rapid 
normalization of an initially abnormal ALT level according 
to genotype are summarized in Figure 2. The SVR rate was 
significantly higher in rapid normalization, especially in 
genotype 1 group compared to genotype non 1 group 
(P=0.01 in genotype 1 group vs. P=0.11 in genotype non-1 
group).
Analysis of factors that predicted sustained 
virological response to combination therapy
We performed univariate analysis using the chi-square 
test to investigate the association of SVR with various 
factors. Age, sex, viral genotype, initial RNA titer, patterns 
of changes in ALT and BMI were selected as possible 
significant factors. In the multiple logistic regression for the 
strength of influence factors, age (OR 0.94; 95% CI 0.91-0.98; 
P-value=0.005), viral genotype (OR 2.76; 95% CI 1.20-6.38; 
P-value=0.017), initial HCV RNA titer (OR 0.28; 95% CI 
0.10-0.75; P-value=0.012) were identified as independent 
significant predictive factors for SVR (Table 3).
Among patients who had initial abnormal ALT levels (Gr 
1-2), the SVR rate was significantly higher in group 2, 
compared with group 1. In the multiple logistic regression, 
compared to group 1, group 2 had significantly higher SVR Yun Jung Kim, et al. Clinical meaning about change in alanine aminotransferase  45
Figure 2. Comparison of virologic responses in patients with or 
without rapid normalization of an initially abnormal ALT level 
according to genotype. Group 1, initially abnormal ALT level 
with rapid normalization (i.e., within 1.5 times the normal range 
of ALT level by 4  weeks after starting treatment). Group 2, 
initially abnormal ALT level without rapid normalization (i.e., 
not within 1.5 times the normal range of ALT level by 4 weeks
after starting treatment). Levels of statistical significance (i.e., 
P) were calculated using the chi-squared test. SVR, sustained 
virologic response. 
Table 3. Independent factors associated with a sustained virologic response (SVR) in chronic hepatitis C (CHC) treatment: multivariate
analysis
Odds ratio 95% CI P-value
Age (years) 0.94 0.91-0.98 0.005
Gender (male) 0.64 0.28-1.46 0.286
Genotype (non-1 type) 2.76 1.20-6.38 0.017
BMI (kg/m
2) 0.93 0.80-1.08 0.332
Initial HCV RNA (<400000)  1.00
   ≥400000, <800000 0.98 0.33-2.98 0.975
   ≥800000 0.28 0.10-0.75 0.012
Group 1 (Abnormal→Abnormal) 1.00
Group 2 (Abnormal→Normal) 10.51 3.68-29.99 <0.001
Group 3 (Normal→Abnormal) 2.51 0.62-10.25 0.199
Group 4 (Normal→Normal) 9.85 2.99-32.37 <0.001
BMI, body mass index; HCV, hepatitis C virus; ALT, alanine aminotransferase.
rate (OR 10.51; 95% CI 3.68-22.99; P<0.001), as well as 
group 4 (OR 9.85; 95% CI 2.99-32.37; P<0.001) (Table 3). 
DISCUSSION
Chronic hepatitis C (CHC) is the third most common 
cause of chronic liver disease and HCC in Korea, following 
hepatitis B virus (HBV) infection and alcohol.
5 The successful 
treatment of CHC is measured by the virological and 
biochemical response and by histological improvement to 
clearance of virus, for preventing liver cirrhosis and HCC. 
There were attempts to determine non-responders as early 
as possible in order to avoid prolonged treatment without 
benefits.
6 In an effort to determine whether patients could be 
preselected for treatment, many studies have attempted to 
identify clinical or virological features that may distinguish 
CHC patients who may or may not respond to interferon 
therapy.
3,7 Those studies showed that pretreatment prognostic 
features statistically associated with favorable response 
included younger age, female gender and absence of 
cirrhosis. Low levels of pretreatment serum HCV RNA and 
the presence of viral genotype other than 1 were also 
reported to be associated with favorable response to CHC 
therapy.
2,3,8 However, there were patients who had responded 
to combination therapy, but did not meet the specified 
pretreatment characteristics.
7 Thus, the effort to identify 
useful predictive markers, especially during treatment is still 
necessary.
In the natural history of HCV infection, it is well known 
that the first detectable biochemical marker is the presence 
of HCV RNA and elevation of ALT level may occur, 
w i t h i n4t o1 2  w e e k s .
9 Although this elevation reflected 
hepatocyte damage, ALT level may fluctuate sometimes, 
and a single value in the normal range can neither rule out 
active infection nor help gauge the severity of underlying 
liver disease.
10 In general, decreased pattern of ALT level is 
the accepted basic indicator of interferon therapeutic effect 
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normalization of ALT level might indicate poor response to 
interferon therapy,
6,11 although the viral response was not 
always associated with biochemical response.
6,12 However, 
Hung et al
6 observed that 13% of CHC patients who 
obtained SVR to standard interferon and ribavirin treatment 
showed persistently elevated ALT levels during treatment; 
in contrast, in the study by Zeuzem et al
13 using peg-interferon 
and ribavirin, 41% of patients did not achieve ALT 
normalization until the end of therapy. These findings seem 
to suggest that lack of ALT normalization is not necessarily 
associated with decreased efficacy of treatment. However, 
this phenomenon has not been systematically characterized, 
and little is known about its incidence and clinical 
characteristics in chronic hepatitis C patients treated with 
peg-interferon and ribavirin combination therapy. 
In our study, we subdivided patients into four groups, 
according to initial ALT levels and ALT variability during 
treatment. In the analysis of virological response according 
to ALT variability, we found significantly different SVR 
rates between the four groups. In particular, compared to 
group 1 (initial abnormal ALT and sustained abnormal ALT 
levels after treatment), group 2 (initial abnormal ALT and 
obtained normal ALT levels after treatment) had significantly 
higher SVR rate, as well as group 4 (initial normal ALT and 
sustained normal ALT levels after treatment). In clinical 
practice, normalization and sustained normal ALT level 
after treatment could be a good predictive factor for obtaining 
SVR.
Rapid normalization of ALT was defined in this study as 
normalization within 1.5 times of normal ALT levels 4 
weeks after treatment. Its concept is similar to rapid 
virological response (RVR), which means undetectable 
serum HCV RNA determined by quantitative PCR after 4 
weeks of treatment, and is rapidly becoming a useful tool for 
predicting treatment outcomes in patients with CHC. 
Indeed, in our analysis, rapid normalization of ALT 4 weeks 
after treatment was a cost effective and useful tool that 
predicted obtaining of SVR as soon as possible. These 
results supported previous reports showing that absence of 
ALT level elevation during treatment was associated with 
SVR,
14 whereas failure to return to normal ALT level was a 
strong predictor of combination treatment failure.
15 Thus, 
SVR rate was significantly associated with ALT normalization 
during combination treatment in patients with initial 
abnormal ALT levels; in particular, rapid normalization of 
ALT during treatment in genotype 1 group might be 
considered as useful response factor in clinical practice, for 
patients with initial abnormal ALT levels.
During the natural course of CHC treatment, some 
patients may continue to show abnormal ALT levels despite 
of virological response. As demonstrated in previous 
studies, these patients had persistent rises in ALT during 
follow-up, but they had eradicated HCV RNA from serum 
and were classified as sustained responders.
16 The reasons 
for this discrepancy remain unclear, but previous studies 
have also indicated that some of these patients may have 
cirrhosis, steatosis, thyroid dysfunction or other potential 
causes for the persistently abnormal biochemical results.
7 In 
our study, 37 patients had persistent abnormal ALT level 
during follow-up, but 37.8% of them had eradicated HCV 
RNA from serum and obtained SVR. Basso et al
17 reported 
the incidence and clinical meaning of elevated ALT in 
chronic hepatitis C virus RNA-negative patients, during 
peg-interferon and ribavirin combination therapy. Among 
173 study patients, 57 patients (33%) had elevated ALT in at 
least one evaluation from initial normal ALT level and the 
authors mentioned that this phenomenon, especially in the 
latter phase of therapy, was more common in relapsing 
patients. Moreover, peg-interferon and ribavirin treatment- 
induced elevations of liver enzymes have been observed, 
and the underlying liver disease might be exacerbated if the 
relationship between viral replication and the host immune 
response is altered. Therefore, in clinical practice, any 
potential cause, as well as the patterns of changes in ALT 
during treatment should be considered.
In our study, to further evaluate the relationship between 
ALT variability during treatment and virologic response 
to peg-interferon and ribavirin combination therapy, we 
stratified four groups by the patterns of change in ALT in 
patients with chronic hepatitis C. Also, the new concept of 
rapid normalization of ALT levels after 4 weeks of treatment 
was closely related to SVR. It is noteworthy that ALT 
variable pattern during peg-interferon and ribavirin com-
bination therapy is a phenomenon that may be encountered 
in clinical practice, although its incidence and clinical 
meaning have not been fully elucidated. To the best of our 
knowledge, no study has been conducted to date, classifying  
patients according to rapid normalization of ALT during 
treatment and investigating the clinical meaning and asso-
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Results of this study are subjected to some limitations. 
First, the study had retrospective and observational design 
and was conducted in a single institution. Thus, our results 
may not reflect a general situation. Second, our analysis was 
carried out in a relatively small number of patients, and it 
will be interesting to determine whether this incidence and 
association holds true in larger groups of patients. Third, we 
did not investigate chronic hepatitis C patients according to 
disease progression, including cirrhosis and hepatocellular 
carcinoma, and did not include patients with liver disease of 
other origins. Thus, in future studies, analysis of ALT variability 
during treatment should be performed according to liver 
status. Fourth, several factors previously known as main 
putative causes for ALT variability, were not investigated in 
our study (i.e. thyroid dysfunction, lipid profile, HOMA-IR, 
the use of herb medication and alcohol consumption).
In conclusion, in patients with initial abnormal ALT 
levels, the SVR rate was significantly associated with ALT 
normalization during combination therapy; ALT normalization 
during treatment might be considered as useful predictive 
factor for obtaining SVR in patients with initial abnormal 
ALT levels. In particular, rapid normalization of ALT 4 
weeks after treatment in genotype 1 group might be 
considered an indicator of favorable response to treatment, 
readily available in clinical practice.
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